Benefit-Risk assessmentMeSH concept

https://ansm.sante.fr/informations-de-securite/ocaliva-acide-obeticholique-recommandation-dabrogation-de-lautorisation-de-mise-sur-le-marche-conditionnelle-dans-lunion-europeenne-en-raison-dun-benefice-clinique-non-confirme
2024
false
false
false
France
French
risk assessment
Benefit-Risk assessment
drug information
obeticholic acid
obeticholic acid
obeticholic acid
Primary Biliary Cholangitis

---
https://ansm.sante.fr/actualites/prevention-de-la-bronchiolite-du-nourrisson-les-premieres-donnees-de-pharmacovigilance-confirment-le-profil-de-securite-du-nirsevimab-beyfortus
2024
false
false
false
France
French
bronchiolitis, viral
infant, newborn
infant
pharmacovigilance
respiratory syncytial virus infections
nirsevimab
nirsevimab
risks and benefits
Benefit-Risk assessment
hospitalization
investigative report
drug information
technical report
nirsevimab

---
https://www.inesss.qc.ca/covid-19/traitements-specifiques-a-la-covid-19/les-fondements-ethiques-de-levaluation-de-lequilibre-benefices-risques-dun-traitement-prometteur-en-contexte-de-pandemie.html
2021
Canada
coronavirus infections
pneumonia, viral
drug information
Benefit-Risk assessment
pandemics
risk assessment
ethical review
Ethics
COVID-19

---
https://www.anses.fr/fr/system/files/VECTEURS2020SA0057.pdf
2020
France
coronavirus infections
pneumonia, viral
public health guidelines
Dengue
inlets
risk assessment
wrestling
engaged in wrestling
risk-taking
albumin/globulin ratio
Control
Benefit-Risk assessment
Dengue fevers
relative risk
dengue
bays
Practice
containment of biohazards
dengue
risk
pandemics
COVID-19

---
Position Statement of the Francophone Diabetes Society (SFD): Evaluation of the risk-benefit ratio of SGLT2 inhibitors
https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/ressources/mmm_isglt2_vf.pdf
2019
false
false
false
false
France
journal article
journal article
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
cardiovascular diseases
cardiovascular diseases
diabetic nephropathies
diabetic nephropathies
algorithms
algorithms
guideline
guideline
risk assessment
risk assessment
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Benefit-Risk assessment
Benefit-Risk assessment
diabetes mellitus, type 2
diabetes mellitus, type 2

---
https://www.anses.fr/fr/content/avis-et-rapport-de-lanses-du-19-novembre-2014-r%C3%A9vis%C3%A9-le-9-janvier-2015-relatifs-%C3%A0-l
2015
false
false
false
false
France
French
scientific and technical information
scientific and technical information
albumin/globulin ratio
albumin/globulin ratio
Benefit-Risk assessment
Benefit-Risk assessment
research report
research report
report
report
relative risk
relative risk
risk assessment
risk assessment
relative
relative
nutrition assessment
nutrition assessment
sweetening agents
sweetening agents
inlets
inlets
risk
risk
bays
bays

---